Anti-BCMA novel therapies for multiple myeloma

被引：15
作者：
Sammartano, Vincenzo [1 ]
Franceschini, Marta [1 ]
Fredducci, Sara [1 ]
Caroni, Federico [1 ]
Ciofini, Sara [1 ]
Pacelli, Paola [1 ]
Bocchia, Monica [1 ]
Gozzetti, Alessandro [1 ,2 ]
机构：
[1] Univ Siena, Azienda Ospedaliero Univ Senese, Dept Med Surg & Neurosci, I-53100 Siena, Italy
[2] Univ Siena, Azienda Ospedaliero Univ Senese, Dept Med Surg & Neurosci, Viale Mario Bracci 16, I-53100 Siena, Italy
来源：
CANCER DRUG RESISTANCE | 2023年 / 6卷 / 01期
关键词：
Multiple myeloma; BCMA; belantamab; teclistamab; CART; CELL MATURATION ANTIGEN; NF-KAPPA-B; BELANTAMAB MAFODOTIN; RECEPTOR; SURVIVAL; OUTCOMES; APRIL; EFFICACY; DISEASE; MEMBER;
D O I：
10.20517/cdr.2022.138
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Recent advances in multiple myeloma therapy have increased the depth of response and ultimately survivals; however, the prognosis remains poor. The BCMA antigen is highly expressed in myeloma cells, thus representing a target for novel therapies. Several agents that target BCMA through different mechanisms, including bispecific T cell engagers drug conjugated to antibody and CAR-T cells, are now available or under development. Immunotherapies targeting BCMA have shown good results in efficacy and safety in multiple myeloma patients previously treated with several lines of therapy. This review will discuss the recent development of anti-BCMA targeted treatments in myeloma, with a special focus on currently available agents.
引用
收藏
页码：169 / 181
页数：13
相关论文
共 142 条
  • [31] Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma
    Feng, Deming
    Sun, Jian
    [J]. SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2020, 92 (02)
  • [32] HDP-101, an Anti-BCMA Antibody-Drug Conjugate, Safely Delivers Amanitin to Induce Cell Death in Proliferating and Resting Multiple Myeloma Cells
    Figueroa-Vazquez, Vianihuini
    Ko, Jonathan
    Breunig, Christian
    Baumann, Anja
    Giesen, Nicola
    Palfi, Aniko
    Mueller, Christoph
    Lutz, Christian
    Hechler, Torsten
    Kulke, Michael
    Mueller-Tidow, Carsten
    Kraemer, Alwin
    Goldschmidt, Hartmut
    Pahl, Andreas
    Raab, Marc S.
    [J]. MOLECULAR CANCER THERAPEUTICS, 2021, 20 (02) : 367 - 378
  • [33] Trends in overall survival and costs of multiple myeloma, 2000-2014
    Fonseca, R.
    Abouzaid, S.
    Bonafede, M.
    Cai, Q.
    Parikh, K.
    Cosler, L.
    Richardson, P.
    [J]. LEUKEMIA, 2017, 31 (09) : 1915 - 1921
  • [34] Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells
    Friedman, Kevin M.
    Garrett, Tracy E.
    Evans, John W.
    Horton, Holly M.
    Latimer, Howard J.
    Seidel, Stacie L.
    Horvath, Christopher J.
    Morgan, Richard A.
    [J]. HUMAN GENE THERAPY, 2018, 29 (05) : 585 - 601
  • [35] Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy
    Gandhi, Ujjawal H.
    Cornell, Robert F.
    Lakshman, Arjun
    Gahvari, Zhubin J.
    McGehee, Elizabeth
    Jagosky, Megan H.
    Gupta, Ridhi
    Varnado, William
    Fiala, Mark A.
    Chhabra, Saurabh
    Malek, Ehsan
    Mansour, Joshua
    Paul, Barry
    Barnstead, Alyssa
    Kodali, Saranya
    Neppalli, Amarendra
    Liedtke, Michaela
    Narayana, Swapna
    Godby, Kelly N.
    Kang, Yubin
    Kansagra, Ankit
    Umyarova, Elvira
    Scott, Emma C.
    Hari, Parameswaran
    Vij, Ravi
    Usmani, Saad Z.
    Callander, Natalie S.
    Kumar, Shaji K.
    Costa, Luciano J.
    [J]. LEUKEMIA, 2019, 33 (09) : 2266 - 2275
  • [36] Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells
    Gattinoni, L
    Finkelstein, SE
    Klebanoff, CA
    Antony, PA
    Palmer, DC
    Spiess, PJ
    Hwang, LN
    Yu, ZY
    Wrzesinski, C
    Heimann, DM
    Surh, CD
    Rosenberg, SA
    Restifo, NP
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 202 (07) : 907 - 912
  • [37] Anti-BCMA antibodies in the future management of multiple myeloma
    Gavriatopoulou, Maria
    Ntanasis-Stathopoulos, Ioannis
    Dimopoulos, Meletios Athanasios
    Terpos, Evangelos
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2019, 19 (04) : 319 - 326
  • [38] Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients
    Ghermezi, Michael
    Li, Mingjie
    Vardanyan, Suzie
    Harutyunyan, Nika Manik
    Gottlieb, Jillian
    Berenson, Ariana
    Spektor, Tanya M.
    Andreu-Vieyra, Claudia
    Petraki, Sophia
    Sanchez, Eric
    Udd, Kyle
    Wang, Cathy S.
    Swift, Regina A.
    Chen, Haiming
    Berenson, James R.
    [J]. HAEMATOLOGICA, 2017, 102 (04) : 785 - 795
  • [39] Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma
    Girgis, Suzette
    Lin, Shun Xin Wang
    Pillarisetti, Kodandaram
    Banerjee, Arnob
    Stephenson, Tara
    Ma, Xuewen
    Shetty, Shoba
    Yang, Tong-Yuan
    Hilder, Brandi W.
    Jiao, Qun
    Hanna, Brett
    Adams, Homer
    Sun, Yu-Nien
    Sharma, Amarnath
    Smit, Jennifer
    Infante, Jeffrey R.
    Goldberg, Jenna D.
    Elsayed, Yusri
    [J]. TARGETED ONCOLOGY, 2022, 17 (04) : 433 - 439
  • [40] Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy
    Gong, Ying
    Klein Wolterink, Roel G. J.
    Wang, Jianxiang
    Bos, Gerard M. J.
    Germeraad, Wilfred T. V.
    [J]. JOURNAL OF HEMATOLOGY & ONCOLOGY, 2021, 14 (01)
12345678910